Download MendeleyStructure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
Bauder, M., Meyners, C., Purder, P.L., Merz, S., Sugiarto, W.O., Voll, A.M., Heymann, T., Hausch, F.(2021) J Med Chem 64: 3320-3349
- PubMed: 33666419
- DOI: https://doi.org/10.1021/acs.jmedchem.0c02195
- Primary Citation of Related Structures:
7A6W, 7A6X, 7AWX, 7B9Y, 7B9Z, 7BA0 - PubMed Abstract:
The FK506-binding protein 51 (FKBP51) emerged as a key player in several diseases like stress-related disorders, chronic pain, and obesity. Linear analogues of FK506 called SAFit were shown to be highly selective for FKBP51 over its closest homologue FKBP52, allowing the proof-of-concept studies in animal models. Here, we designed and synthesized the first macrocyclic FKBP51-selective ligands to stabilize the active conformation. All macrocycles retained full FKBP51 affinity and selectivity over FKBP52 and the incorporation of polar functionalities further enhanced affinity. Six high-resolution crystal structures of macrocyclic inhibitors in complex with FKBP51 confirmed the desired selectivity-enabling binding mode. Our results show that macrocyclization is a viable strategy to target the shallow FKBP51 binding site selectively.
Organizational Affiliation:
Department Chemistry and Biochemistry, Clemens-Schöpf-Institute, Technical University Darmstadt, Alarich-Weiss-Straße 4, 64287 Darmstadt, Germany.
